"randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)" Read more about "randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)"
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity Read more about RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity
"PROSPECTIVE, RANDOMIZED, OPEN LABEL CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE USE BEYOND 24 HOURS COMPARED WITH MIDAZOLAM IN CHILDREN ADMITTED TO PEDIATRIC INTENSIVE CARE UNIT (PICU) AT KASCH-MNGHA. (PROMISE)" Read more about "PROSPECTIVE, RANDOMIZED, OPEN LABEL CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE USE BEYOND 24 HOURS COMPARED WITH MIDAZOLAM IN CHILDREN ADMITTED TO PEDIATRIC INTENSIVE CARE UNIT (PICU) AT KASCH-MNGHA. (PROMISE)"
Prospective, Randomized, Open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Intensive Care unit (PICU) at KAMC-NGHA Read more about Prospective, Randomized, Open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Intensive Care unit (PICU) at KAMC-NGHA
Prospective, Randomized, open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Critical Care unit (PICU) at KAMC-NGHA (PROMISE) Read more about Prospective, Randomized, open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Critical Care unit (PICU) at KAMC-NGHA (PROMISE)
Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency Read more about Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency
Prophylactic Acetaminophen (Panadol) To Prevent the Intraventricular Haemorrhage of Premature Babies. Read more about Prophylactic Acetaminophen (Panadol) To Prevent the Intraventricular Haemorrhage of Premature Babies.
Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA) Read more about Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)
Phase III, Single-arm, Open-label, International, Multi-centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients with Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid-lowering Therapy Read more about Phase III, Single-arm, Open-label, International, Multi-centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients with Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid-lowering Therapy
Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%) Read more about Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)